AbelZeta Regains Global Rights for C-CAR039 and Receives FDA Clearance for IND Application

AbelZeta Pharma, Inc. has successfully regained the global rights for its C-CAR039 (Prizlon-cel) cell therapy. The company also announced on August 16, 2026, that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application, targeting treatment for large B-cell lymphoma.

The regaining of global rights is expected to allow AbelZeta to advance its strategic development objectives more effectively. C-CAR039 is an investigational therapy utilizing Chimeric Antigen Receptor (CAR-T) technology, which has previously demonstrated potential in certain hematological malignancies.

The FDA's clearance of the IND application marks a significant step, enabling the initiation of clinical trials in the United States. This paves the way for evaluating the therapy's potential benefits in a broader patient population. Large B-cell lymphoma is an aggressive cancer for which new treatment options are critically needed.

AbelZeta has now secured the global rights for C-CAR039 from its former partner. The company will proceed with the independent development of the therapy and is preparing to commence clinical studies in the U.S., focusing on large B-cell lymphoma.